The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI

References

Page 1

	Year	Citations
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk, The Lancet Oncology Surgical OncologyEsophageal CancerGastrointestinal OncologyMedicineSurgical Pathology	2016	713
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial Kazumasa Fujitani, Han‐Kwang Yang, Junki Mizusawa, The Lancet Oncology Single Non-curable FactorSurgical OncologyGastrointestinal OncologyAdvanced Gastric CancerMedicine	2016	688
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk, JAMA Oncology	2017	458
Value of palliative resection in gastric cancer H.H. Hartgrink, Hein Putter, Elma Meershoek‐Klein Kranenbarg, British journal of surgery	2002	262
Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases Seong Ha Cheon, Sun Young Rha, Hei‐Cheul Jeung, Annals of Oncology Combined Curative ResectionSurgical OncologyHepatologyGastrointestinal OncologyMedicine	2008	186
NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors Christoph Schulz, Frank Kullmann, Volker Kunzmann, International Journal of Cancer Surgical OncologyPerioperative TreatmentGastroesophageal JunctionGastrointestinal OncologyMedicine	2014	123
Long-term Survival and Prognostic Factors in Patients with Metastatic Gastric Cancers Treated with Chemotherapy in the Japan Clinical Oncology Group (JCOG) Study Masayuki Yoshida Japanese Journal of Clinical Oncology	2004	109
Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5‐fluorouracil, oxaliplatin and docetaxel Nils Homann, Claudia Pauligk, Kim Barbara Luley, International Journal of Cancer Surgical OncologyEsophageal CancerColorectal SurgeryCancer ManagementGastroenterology	2011	98
Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S-1-based chemotherapy: a multi-institute retrospective study Tatsuo Kanda, Kazuhito Yajima, Shin‐ichi Kosugi, Gastric Cancer Multi-institute Retrospective StudySurgical OncologyS-1-based ChemotherapySecondary SurgeryGastrointestinal Oncology	2011	64
Efficacy of pre‐operative chemotherapy with docetaxel, cisplatin, and S‐1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para‐aortic lymph nodes Katsunobu Oyama, Sachio Fushida, Jun Kinoshita, Journal of Surgical Oncology	2011	52

Page 1